A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma
PRIMARY OBJECTIVES:
I. To evaluate the overall response rate (combined complete remission [CR] and partial
remission [PR]) of AZD6244 hyd-sulfate anti-MEK (selumetinib) therapy for patients with
relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of MEK inhibitor therapy. II. To determine the
progression-free survival, time to treatment failure, duration of response, and overall
survival with AZD6244 hyd-sulfate therapy.
III. To examine biomarkers through down-regulation of pERK and several relevant target
substrates (e.g., MCT-1, MNK, ELK, c-MYC, and HIF-1alpha) in peripheral blood studies.
OUTLINE: This is a multicenter study.
Patients receive selumetinib orally (PO) twice daily on days 1-28. Treatment repeats every
28 days for 8 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample and tumor tissue collection at baseline and at day 15 of
course 1 for biomarker studies.
After completion of study therapy, patients are followed up every 3 months for up to 3
years.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate (complete response and partial response) in patients treated with selumetinib
Estimates of the response rate based on best response [complete response (CR), and partial response (PR)] and the tumor control rate [CR, PR, and stable disease (SD)] will be provided together with the exact two-sided 95% confidence intervals.
Up to 3 years
No
Leo Gordon
Principal Investigator
University of Chicago Comprehensive Cancer Center
United States: Food and Drug Administration
NCI-2011-02558
NCT01278615
December 2010
Name | Location |
---|---|
Ingalls Memorial Hospital | Harvey, Illinois 60426 |
Weill Medical College of Cornell University | New York, New York 10021 |
Northwestern University | Chicago, Illinois 60611 |
University of Massachusetts Medical School | Worcester, Massachusetts 01605 |
Indiana University Medical Center | Indianapolis, Indiana 46202 |
Decatur Memorial Hospital | Decatur, Illinois 62526 |
University of Chicago Comprehensive Cancer Center | Chicago, Illinois 60637-1470 |
Evanston CCOP-NorthShore University HealthSystem | Evanston, Illinois 60201 |
Illinois CancerCare-Peoria | Peoria, Illinois 61615 |
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard | Fort Wayne, Indiana 46845 |
Saint John's Mercy Medical Center | Saint Louis, Missouri 63141 |
University of Maryland Greenebaum Cancer Center | Baltimore, Maryland 21201 |
University of Michigan University Hospital | Ann Arbor, Michigan 48109 |
Saint Joseph Medical Center | Towson, Maryland 21204 |
Southern Illinois University | Springfield, Illinois 62702 |